ArticleMolecular cancer2025

IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC.

Yanan Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.